Back to search results

Genetics of Appendix Cancer Study

This study, called the Genetics of Appendix Cancer (GAP) Study, is looking into the genetic changes that might lead to appendix cancer. Researchers will use genetic profiling (whole exome sequencing) to examine your DNA and collect archived tumor tissues that were previously removed. The goal is to understand the prevalence and types of genetic changes found in people with appendix cancer and their biological parents. You can join if you are 18 or older, have been diagnosed with appendix cancer in the United States, and are able to give consent and participate. The study status is currently unclear, but it plans to enroll 700 participants.

Study design
This is an observational study, meaning participants are not given new treatments but are studied over time. It aims to enroll 700 participants.
What's involved
You would provide genetic samples for whole exome sequencing and allow researchers to collect archived tumor tissues. You will be followed for up to 6 years after joining the study.
Compensation
Not stated in the trial record.
Follow-up
Participants are followed for up to 6 years after study enrollment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05734430

Genetics of Appendix Cancer Study

Recruiting
Not specifiedAges 18+Observational
Andreana Holowatyj, PhD, MSCI
~700 participants
Updated 2025-04-18 on ClinicalTrials.gov
What's tested:Genetic profilingRetrospective tissue procurement

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Prevalence and spectrum of pathogenic and likely pathogenic germline variants in appendix cancer patients and their biological parents
Measured over Within 6 years of study enrollment

Conditions

Appendix Cancer
Appendiceal Cancer
Appendiceal Neoplasms
Appendiceal Mucinous Neoplasm
Appendiceal Adenocarcinoma
Appendiceal Carcinoid Tumor
Appendiceal Neoplasm Malignant Secondary
Appendix Adenocarcinoma
Appendix Mucinous Neoplasm
Appendix Tumor
Appendix Cancer Metastatic
Appendix NET
Low-Grade Appendix Mucinous Neoplasm
High Grade Appendix Mucinous Neoplasm
High Grade Appendix Mucinous Adenocarcinoma

Explore related trials

Appendix Carcinoma

Where it's being run

1 sites across 1 states
Tennessee1

Study leadership

  • Andreana N Holowatyj, PhD, MSCI · PRINCIPAL_INVESTIGATOR · Vanderbilt-Ingram Cancer Center

Who to contact

GAP Study Coordinator (Rebecca B.)
[email protected]
615-936-8544
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Known diagnosis of appendix cancer in the United States
Mentally and physically able to consent and participate in the study
Known diagnosis of appendix cancer
Diagnosed by and/or consulting with a physician/clinical provider participating in the GAP Study
Mentally and physically able to consent and participate in the study
Biological parents (mother and/or father) of individuals actively participating in the GAP Study
Residing in the United States
Mentally and physically able to consent and participate in the study

Exclusion

Women pregnant at the time of consent
Prisoners
Unable to provide informed consent
Unable to read, write, or complete questionnaires in English

What this trial measures

  • Prevalence and spectrum of pathogenic and likely pathogenic germline variants in appendix cancer patients and their biological parentsWithin 6 years of study enrollment